英文字典中文字典51ZiDian.com

中文字典辞典英文字典 a b c d e f g h i j k l m n o p q r s t u v w x y z

evolute

n. 渐屈线
a. 渐屈的

渐屈线渐屈的

The Collaborative International Dictionary of English v.0.48 (gcide)

Evolute \Ev"o*lute\, n. [L. evolutus unrolled, p. p. of
evolvere. See {Evolve}.] (Geom.)
A curve from which another curve, called the involute or
evolvent, is described by the end of a thread gradually wound
upon the former, or unwound from it. See {Involute}. It is
the locus of the centers of all the circles which are
osculatory to the given curve or evolvent.
[1913 Webster]

Note: Any curve may be an evolute, the term being applied to
it only in its relation to the involute.
[1913 Webster]

请选择你想看的字典辞典：

单词	字典	翻译
evolute	查看　evolute　在百度字典中的解释	百度英翻中〔查看〕
evolute	查看　evolute　在Google字典中的解释	Google英翻中〔查看〕
evolute	查看　evolute　在Yahoo字典中的解释	Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!

中文字典英文字典工具:

选择颜色:

<style type="text/css">#word104_1 br {display:none;}</style>
<form id="word104_1" method="post" action="http://www.51zidian.com/index.php" target="_blank">
<div style="width: 140px;border:1px solid #000;background-color:#ffffff;padding: 0px 0px;margin: 0px 0px;align:center;text-align:center;overflow:hidden;"><div id="xcolor1_1" style="font-size:12px;color:#183a00;line-height:16px;font-family: arial; font-weight:bold;background:#94abf0;padding: 3px 1px;text-align:center;"><a href="http://www.51zidian.com/" alt="英文字典中文字典" title="英文字典中文字典" id="word_name104_1" style="color:#000000;font-size:14px;text-decoration:none;line-height:16px;font-family: arial;" >英文字典中文字典</a></div><table width=100% style='align:center;text-align:left;font-size:12px;background-color:#ffffff;color:#333333;'>
<tr><td style="text-align:center;border:0"><input type=hidden name="word104_hi" value="1">输入中英文单字</td></tr><tr><td style="text-align:center;border:0"><input type="text" name="word104_input" value="" size=10 style="background-color:#ffffff;color:#000;text-decoration:none;font-family: arial;rial;border:1px solid #999;padding:1px!important;"></td></tr><tr style='line-height: 26px;'><td style="text-align:center;border:0"><input type=submit style="background-color:#ccc;color:#000;border:0 none;cursor:pointer;" value="查询字典"></td></tr></table></div>
</form>

英文字典中文字典相关资料:

Chronic Kidney Disease Treatment | FARXIGA® (dapagliflozin)
For adults with chronic kidney disease (CKD), FARXIGA is a prescription medicine approved to reduce the risk of further worsening of kidney disease, end-stage kidney disease, death due to cardiovascular disease, and hospitalization for heart failure
Dapagliflozin in Patients with Chronic Kidney Disease
We designed the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial to assess the long-term efficacy and safety of the SGLT2 inhibitor dapagliflozin in
Farxiga: Uses, Dosage, Side Effects Warnings - Drugs. com
Farxiga works by inhibiting sodium-glucose cotransporter 2 (SGLT2), which is present in the proximal renal tubules and reabsorbs filtered glucose By inhibiting this, Farxiga promotes the excretion of glucose in the urine
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes
How Does Farxiga Work for Chronic Kidney Disease (CKD)? - Kidney Health MD
Farxiga is an effective drug because it is focused on SGLT2 protein in the kidney in order to assist those suffering from Chronic Kidney Disease Through this process, we want to learn about the working of the mechanism and the impact for people suffering with this chronic health concern
Farxiga approved in the US for the treatment of chronic kidney disease . . .
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease
Farxiga Approved for Patients With CKD at Risk of Progression
The Food and Drug Administration (FDA) has approved Farxiga ® (dapagliflozin) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease,

中文字典-英文字典 2005-2009